Clinical trials: Neurocognitive Disorders, Mild
Mild Cognitive Impairment, Cognitive Impairment
SNIFF - Combo INI+EMPA Trial
The proposed pilot study will provide safety and efficacy preliminary data regarding singular and combined effects of two therapeutic approaches, intranasal insulin and treatment with the sodium-glucose cotransporter type 2…
- Conditions
- Mild Cognitive Impairment, Cognitive Impairment, Alzheimer Disease
- Trial name
- NCT05081219
- Testing
- Insulin (Humulin® R U-100), Empagliflozin 10 MG, Aptar Pharma CPS Intranasal Delivery Device
- Where
- United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Mild Cognitive Impairment, Alzheimer Disease
Effect of Blueberry Supplementation on Alzheimer's Biomarkers
The purpose of this study is to study the effects of blueberries on neuronal, glial, and pathology blood biomarkers in Mild Cognitive Impairment (MCI) and to estimate sample size for future confirmatory studies.
- Trial name
- NCT05172128
- Testing
- lyophilized blueberry supplement
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Duke University
Cognitive Impairment, Mild, Cognitive Decline
Efficacy of a Multimodal Brain Health Intervention for Older African Americans
This study tests the feasibility, acceptability, and efficacy of a multimodal intervention (walking, social engagement, and reminiscence), including the use of wearable digital biomarkers, for cognitively healthy and mildly…
- Trial name
- SHARP (NCT04863378)
- Testing
- Walking conversational reminiscence
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Oregon Health and Science University
Alzheimer's Disease
Study of SB-742457 or Donepezil Versus Placebo in Subjects With Mild-to-moderate Alzheimer's Disease
The study is designed to investigate the efficacy, safety and tolerability of SB-742457 versus placebo in subjects with mild-to-moderate Alzheimer's disease.
- Trial name
- NCT00708552
- Testing
- SB-742457, Donepezil
- Where
- 72 sites in Bulgaria, Chile and 9 more
- Volunteers
- 576 people
- Sponsor
- GlaxoSmithKline
Alzheimer's Disease, Mild Cognitive Impairment
A PET Study of the Effects of p38 MAP Kinase Inhibitor, VX-745, on Amyloid Plaque Load in Alzheimer's Disease (AD)
This study will assess the effects of administration of VX-745 for 12 weeks on amyloid plaque burden in Alzheimer's disease (AD).
- Trial name
- NCT02423122
- Testing
- VX-745
- Where
- Netherlands
- Volunteers
- 16 people
- Sponsor
- EIP Pharma Inc
Dementia
Prazosin and Cerebrospinal Fluid (CSF) Biomarkers in Mild Traumatic Brain Injury (mTBI)
Mild traumatic brain injury (mTBI) from explosions is the "signature injury" of Veterans who have deployed to the wars in Afghanistan and Iraq.
- Trial name
- PoND (NCT03221751)
- Testing
- prazosin hydrochloride
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- VA Office of Research and Development
Alzheimer's Disease
A Study to Evaluate the Safety, Tolerability, and Blood Levels of PF-03654746 in Subjects With Mild to Moderate Alzheimer's Disease
This is a study to evaluate the safety, tolerability and blood levels of PF-03654746 in subjects will mild to moderate Alzheimer's disease.
- Trial name
- NCT01028911
- Testing
- PF-03654746
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Pfizer
Dementia, Alzheimer Disease
Digital Interventions in Neuro-Rehabilitation: Gotcha!
Aims and background Everyone forgets the names of people they should know at times. Having dementia makes this problem worse. People with dementia have told expressed they forget the names of people they care about and this can…
- Conditions
- Dementia, Alzheimer Disease, Anomia
- Trial name
- NCT04570215
- Testing
- Gotcha! Therapy application, Gotcha Therapy application: Maintenance
- Where
- United Kingdom
- Volunteers
- 48 people
- Sponsor
- University College, London
Mild Cognitive Impairment, Healthy Aging
SHARE(D) Stage II: Alzheimer's Risk Disclosure Protocol Piloting
The goal of this study is to test efficacy and safety of person-centered, culturally-informed protocols for disclosure of different combinations of Alzheimer's dementia risk factors.
- Trial name
- SHARE(D) (NCT04309500)
- Testing
- Personalized DAT Risk Disclosure Protocol
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Michigan
Alzheimer's Disease, Mild Cognitive Impairment
A Pilot Clinical Trial of Exendin-4 in Alzheimer's Disease
Background: Exendin-4 (or Exenatide) is a medication currently used to treat diabetes that has shown promising results in animal and cellular models of Alzheimer's disease.
- Trial name
- NCT01255163
- Testing
- Exendin-4 SC
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- National Institute on Aging (NIA)
Alzheimer Disease
Study Evaluating ACC-001 in Japanese Patients With Mild To Moderate Alzheimer's Disease
The study is to evaluate the safety, tolerability and whether there is an immune system response to multiple doses of ACC-001 with or without the use of a substance that may increase the response to the drug.
- Trial name
- NCT00752232
- Testing
- ACC-001, QS-21, PBS
- Where
- 10 sites in Japan
- Volunteers
- 40 people
- Sponsor
- Pfizer
Aging, Mild Cognitive Impairment
tDCS and Cognitive Efficiency in Ageing
Normal aging is associated with a progressive decline in cognitive functions, especially memory. This decline in cognitive function can negatively impact the quality of life of older adults.
- Conditions
- Aging, Mild Cognitive Impairment, Alzheimer Disease
- Trial name
- FRtDCS (NCT05216315)
- Testing
- Transcranial direct current stimulation (tDCS)
- Where
- Spain
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- University of Valencia
HIV-related Mild Neurocognitive Disorder
Computer Training and Transcranial Direct Current Stimulation for Cognition in HIV
This study investigates the effectiveness of computer-based cognitive training with or without transcranial direct current stimulation (tDCS) in improving the functioning of older individuals with HIV-related cognitive…
- Trial name
- NCT03440840
- Testing
- Transcranial Direct Current Stimulation (tDCS), Computer-based Cognitive Training, Watching Educational Videos
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Nova Southeastern University
Mild Cognitive Impairment
Enhancing Cognitive Control in Mild Cognitive Impairment Via Non-invasive Brain Stimulation
The overall goal of this project is to improve cognitive control abilities in adults with mild cognitive impairment (MCI) through a form of non-invasive brain stimulation, transcranial alternating current stimulation (tACS).
- Trial name
- NCT04647032
- Testing
- Transcranial alternating current stimulation
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Mild Cognitive Impairment, Alzheimer's Disease
Minocycline in Patients With Alzheimer's Disease
Cognitively normal individuals, patients with Mild Cognitive Impairment (MCI) or Alzheimer's Disease (AD) will undergo clinical screening, neuropsychological tests, blood and urine analyses, quantitative magnetic resonance…
- Trial name
- NCT01463384
- Testing
- Minocycline
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Huntington Medical Research Institutes
Alzheimer Disease
Comparative Efficacy, Safety, and Tolerability of Rivastigmine 10 and 15 cm^2 Patch in Patients With Alzheimer's Disease (AD) Showing Cognitive Decline
The purpose of this study was to support the optimal use of rivastigmine patch in long-term treatment of Alzheimer's Disease in patients demonstrating functional and cognitive decline at the target maintenance dose of…
- Trial name
- NCT00506415
- Testing
- Rivastigmine 5 cm^2, Rivastigmine 10 cm^2, Rivastigmine 15 cm^2
- Where
- 145 sites in United States, Canada and 5 more
- Volunteers
- 1,584 people
- Sponsor
- Novartis Pharmaceuticals
Alzheimer's Disease
Study Of Rosiglitazone XR In Subjects With Mild-to-Moderate Alzheimers
This is a Phase III, multicenter, open-label extension, single-group study in male and female outpatients with mild-to-moderate Alzheimer's disease (AD) who have completed AVA105640.
- Trial name
- NCT00550420
- Testing
- Rosiglitazone XR
- Where
- 70 sites in United States, Austria and 16 more
- Volunteers
- 331 people
- Sponsor
- GlaxoSmithKline
Mild Cognitive Impairment
Candesartan's Effects on Alzheimer's Disease And Related Biomarkers
This study is intended to investigate the safety of candesartan, a blood pressure medication, in non-hypertensive individuals who have mild cognitive impairment (MCI) due to Alzheimer's disease and its effect on disease…
- Trial name
- CEDAR (NCT02646982)
- Testing
- Candesartan
- Where
- 2 sites in United States
- Volunteers
- 77 people
- Sponsor
- Emory University
Alzheimer's Disease
Safety and Efficacy of Donepezil in Mild to Moderate Alzheimer's Disease
This study will evaluate the safety and Efficacy of donepezil in treatment of AD patients in China.
- Trial name
- STDMMAD (NCT02787746)
- Testing
- Donepezil
- Where
- China
- Volunteers
- 241 people
- Sponsor
- Beijing Friendship Hospital
Alzheimer's Disease
3-month Study of MSDC-0160 Effects on Brain Glucose Utilization, Cognition & Safety in Subjects With Alzheimer's Disease
This study will evaluate the effect of 150 mg MSDC-0160 taken daily for 90 days compared to the effect of placebo on changes in brain glucose utilization using FDG-PET and cognition in older persons with mild Alzheimer's disease.
- Trial name
- NCT01374438
- Testing
- MSDC-0160
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Metabolic Solutions Development Company